Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Tag Archive for: AAV
AI specialist WhiteLab Genomics, the Vision Institute, and IT expert ADLIN Science, have entered into a strategic partnership aimed at developing new AAV vectors targetting retinal dystrophies.
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
Biovian Oy’s second generation AAV platform will include Remedium Bio Inc.’s lead treatment candidate against Osteoarthritis.